ophthalmic solutions

Summary

Summary: Sterile solutions, essentially free from foreign particles and suitably compounded and dispensed, for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. (From Dorland, 27th ed)

Top Publications

  1. ncbi Preservatives in eyedrops: the good, the bad and the ugly
    Christophe Baudouin
    Department of Ophthalmology III, Quinze Vingts National Ophthalmology Hospital, INSERM, U968, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, CNRS, UMR_7210, Paris F 75012, France
    Prog Retin Eye Res 29:312-34. 2010
  2. ncbi The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
    Michael A Kass
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Ophthalmol 120:701-13; discussion 829-30. 2002
  3. ncbi Management of dry eye disease
    Michael A Lemp
    Georgetown University, and OcuSense, Inc, Washington, DC, USA
    Am J Manag Care 14:S88-101. 2008
  4. ncbi Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial
    M Cristina Leske
    Department of Preventive Medicine, Stony Brook University School of Medicine, Health Sciences Center, L3 086, Stony Brook, NY 11794 8036, USA
    Arch Ophthalmol 121:48-56. 2003
  5. doi Topical ophthalmic cyclosporine: pharmacology and clinical uses
    Eric Donnenfeld
    Ophthalmic Consultants of Long Island and Connecticut, Rockville Centre, New York 11570, USA
    Surv Ophthalmol 54:321-38. 2009
  6. doi Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression
    Canan Gürdal
    Ankara Ataturk Training and Research Hospital, 2nd Ophthalmology Department, Ankara, Turkey
    Curr Eye Res 35:771-7. 2010
  7. doi Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension
    Almira Chabi
    Merck Sharp and Dohme Corp, PO Box 1000, North Wales, PA 19454 1099, USA
    Am J Ophthalmol 153:1187-96. 2012
  8. ncbi Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction
    Henry D Perry
    Ophthalmic Consultants of Long Island, Rockville Centre, New York 11570, USA
    Cornea 25:171-5. 2006
  9. pmc Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay
    Hong Liang
    Paris Descartes University, Faculty of Biological and Pharmacological Sciences, Department of Toxicology, Paris, France
    Mol Vis 15:1690-9. 2009
  10. ncbi Clinical performance of a mid-viscosity artificial tear for dry eye treatment
    Peter A Simmons
    Eye Care Research and Development, Allergan LLC, Irvine, CA 92612, USA
    Cornea 26:294-302. 2007

Detail Information

Publications295 found, 100 shown here

  1. ncbi Preservatives in eyedrops: the good, the bad and the ugly
    Christophe Baudouin
    Department of Ophthalmology III, Quinze Vingts National Ophthalmology Hospital, INSERM, U968, UPMC Univ Paris 06, UMR_S 968, Institut de la Vision, CNRS, UMR_7210, Paris F 75012, France
    Prog Retin Eye Res 29:312-34. 2010
    ..roles of the active compound and the preservative in inducing the toxic and/or proinflammatory effects of ophthalmic solutions, is still being debated...
  2. ncbi The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
    Michael A Kass
    Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63110, USA
    Arch Ophthalmol 120:701-13; discussion 829-30. 2002
    ..There is no consensus on the efficacy of medical treatment in delaying or preventing the onset of POAG in individuals with elevated IOP. Therefore, we designed a randomized clinical trial, the Ocular Hypertension Treatment Study...
  3. ncbi Management of dry eye disease
    Michael A Lemp
    Georgetown University, and OcuSense, Inc, Washington, DC, USA
    Am J Manag Care 14:S88-101. 2008
    ..Treatment selection is guided primarily by DED severity. Recently published guidelines propose a severity classification based on clinical signs and symptoms, with treatment recommendations according to severity level...
  4. ncbi Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial
    M Cristina Leske
    Department of Preventive Medicine, Stony Brook University School of Medicine, Health Sciences Center, L3 086, Stony Brook, NY 11794 8036, USA
    Arch Ophthalmol 121:48-56. 2003
    ..To assess factors for progression in the Early Manifest Glaucoma Trial (EMGT), including the effect of EMGT treatment...
  5. doi Topical ophthalmic cyclosporine: pharmacology and clinical uses
    Eric Donnenfeld
    Ophthalmic Consultants of Long Island and Connecticut, Rockville Centre, New York 11570, USA
    Surv Ophthalmol 54:321-38. 2009
    ..As these disorders are often refractory to other available treatments, ophthalmic cyclosporine is a welcome nontoxic adjunct or replacement to potentially toxic topical or systemic immunosuppressive therapies...
  6. doi Topical cyclosporine in thyroid orbitopathy-related dry eye: clinical findings, conjunctival epithelial apoptosis, and MMP-9 expression
    Canan Gürdal
    Ankara Ataturk Training and Research Hospital, 2nd Ophthalmology Department, Ankara, Turkey
    Curr Eye Res 35:771-7. 2010
    ..To evaluate the effects of topical cyclosporine A (CsA) 0.05% (Restasis) on the signs and symptoms of dry eye, on apoptosis, and on MMP-9 expression in conjunctiva epithelial cells in thyroid orbitopathy (TO)-related dry eye patients...
  7. doi Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension
    Almira Chabi
    Merck Sharp and Dohme Corp, PO Box 1000, North Wales, PA 19454 1099, USA
    Am J Ophthalmol 153:1187-96. 2012
    ..To compare the efficacy and safety of tafluprost, a preservative-free (PF) prostaglandin analogue, with PF timolol in patients with open-angle glaucoma or ocular hypertension...
  8. ncbi Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction
    Henry D Perry
    Ophthalmic Consultants of Long Island, Rockville Centre, New York 11570, USA
    Cornea 25:171-5. 2006
    ..To investigate the efficacy of topical cyclosporine A 0.05% (tCsA) (Restasis, Allergan Pharmaceuticals) in the treatment of meibomian gland dysfunction (posterior blepharitis)...
  9. pmc Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay
    Hong Liang
    Paris Descartes University, Faculty of Biological and Pharmacological Sciences, Department of Toxicology, Paris, France
    Mol Vis 15:1690-9. 2009
    ..005% latanoprost, 0.004% travoprost, 0.03% bimatoprost (containing 0.02%, 0.015%, and 0.005% BAC, respectively), and 0.005% latanoprost in a new cationic emulsion (LCEm) formulation...
  10. ncbi Clinical performance of a mid-viscosity artificial tear for dry eye treatment
    Peter A Simmons
    Eye Care Research and Development, Allergan LLC, Irvine, CA 92612, USA
    Cornea 26:294-302. 2007
    ..We report the results of 3 studies conducted to evaluate the performance of a 1.0% carboxymethylcellulose (CMC) mid-viscosity artificial tear compared to currently marketed low-viscosity tears...
  11. ncbi A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance
    Stephen C Pflugfelder
    Baylor College of Medicine, Houston, Texas, USA
    Am J Ophthalmol 138:444-57. 2004
    ..To evaluate loteprednol etabonate ophthalmic 0.5% suspension, versus placebo for treatment of the inflammatory component of keratoconjunctivitis sicca in patients with delayed tear clearance...
  12. pmc Autologous serum eye drops for ocular surface disorders
    G Geerling
    Department of Ophthalmology, University of Lubeck, Ratzeburger Allee 160, D 23538, Germany
    Br J Ophthalmol 88:1467-74. 2004
    ..In view of legislative restrictions and based upon the literature reviewed here a preliminary standard operating procedure for the manufacture of serum eye drops is proposed...
  13. ncbi Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model
    T Fujihara
    Santen Pharmaceutical Co, Ltd, Nara Research and Development Center, Japan
    Invest Ophthalmol Vis Sci 42:96-100. 2001
    ..Accordingly, the effects of such an agonist INS365 on these parameters were characterized in a rat dry eye model...
  14. ncbi The economic burden of dry eye: a conceptual framework and preliminary assessment
    Prabashni Reddy
    Abt Associates Inc, 55 Wheeler Street, Cambridge, Massachusetts 02138, USA
    Cornea 23:751-61. 2004
    ..To develop a conceptual framework for analyzing the economic burden of dry eye and a preliminary assessment of key factors that contribute to that burden...
  15. ncbi [A new approach for better comprehension of diseases of the ocular surface]
    C Baudouin
    Centre National d Ophtalmologie des Quinze Vingts, Paris, France
    J Fr Ophtalmol 30:239-46. 2007
    ....
  16. ncbi Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A
    F Brignole
    Laboratory of Immunohematology and the. Department of Ophthalmology, , APHP, , Boulogne, France
    Invest Ophthalmol Vis Sci 42:90-5. 2001
    ..This study confirms that cyclosporin A may be efficient in reducing conjunctival inflammation in moderate to severe KCS and is consistent with clinical results in this indication...
  17. ncbi Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase
    Yoriko Nakanishi
    Division of Ophthalmology, Department of Organs Therapeutics, Kobe University Graduate School of Medicine, 7 5 2 Kusunoki cho, Chuo Ku, Kobe 650 0017, Japan
    Exp Eye Res 83:1108-17. 2006
    ..05), but not of Akt. Taken together, the present findings suggest that latanoprost rescues retinal neurons and/or glial cells from apoptosis, which is probably mediated by p44/p42 MAPK through caspase-3 inhibition...
  18. pmc Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride
    H Liang
    Department of Toxicology, Faculty of Biological and Pharmacological Sciences, University Paris Descartes, Paris, France
    Br J Ophthalmol 92:1275-82. 2008
    ..To compare the conjunctival and corneal reactions of commercially available solution of latanoprost (Xalatan) and preservative-free (PF) tafluprost in rabbits...
  19. ncbi The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study
    Jost Hillenkamp
    The Eye Hospital, Heinrich Heine University, Dusseldorf, Germany
    Ophthalmology 109:845-50. 2002
    ..To evaluate the efficacy of cidofovir 1% eyedrops with and without cyclosporin A 1% eyedrops as a treatment of acute adenoviral keratoconjunctivitis (AKC)...
  20. doi Clinical review: topical ophthalmic use of cyclosporin A
    Canan Asli Utine
    The Ocular Surface Diseases and Dry Eye Clinic, The Wilmer Eye Institute, Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21287, USA
    Ocul Immunol Inflamm 18:352-61. 2010
    ..This article aims to evaluate the peer-reviewed published scientific literature and to define well-established uses of CsA eyedrops in the field of ocular surface diseases...
  21. doi German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye
    Carl Erb
    Ophthalmology Department, Schlosspark Clinic, Heubnerweg 2, 14059, Berlin, Germany
    Graefes Arch Clin Exp Ophthalmol 246:1593-601. 2008
    ..The purpose of this register was to determine the links between glaucoma, age, concomitant disease, medication, and dry eye in a large group of glaucoma patients...
  22. ncbi Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis
    Adil Kilic
    Department of Opthalmology, Tatvan Military Hospital, Turkey
    Can J Ophthalmol 41:693-8. 2006
    ..A double-masked, placebo-controlled trial to evaluate the short-term efficacy and safety of topical 2% cyclosporine A in preservative-free artificial tears for patients with vernal keratoconjunctivitis...
  23. ncbi Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis
    Michael Rubin
    Department of Ophthalmology, University of Chicago, Chicago, IL 60605, USA
    J Ocul Pharmacol Ther 22:47-53. 2006
    ..These findings should be further evaluated in large-scale, controlled, clinical trials...
  24. ncbi Minimal clinically important difference for the ocular surface disease index
    Kimberly L Miller
    ICON Clinical Research, 188 Embarcadero, Ste 200, San Francisco, CA 94105, USA
    Arch Ophthalmol 128:94-101. 2010
    ....
  25. doi Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects
    Hideki Mochizuki
    Department of Ophthalmology and Visual Science, Graduate School of Biomedical Science, Hiroshima University, Minami Ku, Hiroshima, Japan
    Jpn J Ophthalmol 54:286-90. 2010
    ..To compare the intraocular pressure (IOP) reduction over 24 h achieved with tafluprost (0.0015%) with that achieved with latanoprost (0.005%)...
  26. doi A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome
    Eun Chul Kim
    Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea
    Am J Ophthalmol 147:206-213.e3. 2009
    ..To compare the efficacy of vitamin A (retinyl palmitate) and cyclosporine A 0.05% eye drops in treating patients with dry eye disease...
  27. doi Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial
    Rajesh Sinha
    Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, 110029, India
    Graefes Arch Clin Exp Ophthalmol 248:1167-72. 2010
    ..To evaluate the efficacy and safety of topical cyclosporine A 2% in the prevention of graft rejection in high-risk keratoplasty...
  28. ncbi ESCRS Binkhorst lecture 2002: Pseudophakic preservative maculopathy
    Kensaku Miyake
    Shohzankai Medical Foundation, Miyake Eye Hospital, Nagoya, Japan
    J Cataract Refract Surg 29:1800-10. 2003
    ....
  29. ncbi Lactoferrin protects against UV-B irradiation-induced corneal epithelial damage in rats
    T Fujihara
    Santen Pharmaceutical Co, Ltd Nara Research and Development Center, Ikoma shi, Japan
    Cornea 19:207-11. 2000
    ..To investigate the protective effect of lactoferrin containing eyedrops against UV-B-induced corneal damage in vivo, we examined lactoferrin efficacy in a rat UV-B keratitis model...
  30. ncbi Cyclosporine A 1% eye drops for the treatment of subepithelial infiltrates after adenoviral keratoconjunctivitis
    Bennie H Jeng
    Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA
    Cornea 30:958-61. 2011
    ....
  31. pmc Acupuncture for dry eye: a multicentre randomised controlled trial with active comparison intervention (artificial tear drop) using a mixed method approach protocol
    Tae Hun Kim
    Acupuncture, Moxibustion and Meridian Research Centre, Korea Institute of Oriental Medicine, Daejeon, South Korea
    Trials 11:107. 2010
    ..Therefore, this study was designed both to avoid the flaws of the existing trials and to assess the effectiveness, cost-effectiveness and qualitative characteristics of acupuncture treatment for dry eye...
  32. pmc Trehalose protects corneal epithelial cells from death by drying
    T Matsuo
    Department of Ophthalmology, Okayama University Medical School, Okayama City 700 8558, Japan
    Br J Ophthalmol 85:610-2. 2001
    ..This study was designed to examine whether trehalose could protect corneal epithelial cells in culture from death by desiccation in order to test trehalose as a potential new eye drop for dry eye syndrome...
  33. ncbi The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo
    Pertti Pellinen
    Santen Oy, Tampere, Finland
    Curr Eye Res 37:145-54. 2012
    To investigate the cytotoxicity of benzalkonium chloride (BAC)-containing ophthalmic solutions of prostaglandin analogs (latanoprost, travoprost, bimatoprost, and preservative-free (PF) tafluprost), BAC mixture (BACmix) and BAC homologs ..
  34. ncbi Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells
    David A Ammar
    Rocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver School of Medicine, Aurora, 80045, USA
    Adv Ther 27:837-45. 2010
    ..Substitution of BAK with polyquad or sofZia resulted in significantly higher percentages of live conjunctival and corneal cells. Further studies are needed to understand the- clinical implications of these findings...
  35. ncbi Eye mucosa: an efficient vaccine delivery route for inducing protective immunity
    Kyoung Yul Seo
    Institute for Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea
    J Immunol 185:3610-9. 2010
    ..On the basis of these findings, we propose that the eyedrop route is an alternative to mucosal routes for administering vaccines...
  36. pmc Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model
    Su Khoh-Reiter
    Drug Safety Research and Development, Pfizer Inc, San Diego, CA 92121, USA
    BMC Ophthalmol 9:5. 2009
    Benzalkonium chloride (BAC) is a common preservative used in ophthalmic solutions. The aim of this study was to compare the cytotoxic effects of BAC-containing ophthalmic solutions with a BAC-free ophthalmic solution using an organotypic ..
  37. doi Occludin gene expression as an early in vitro sign for mild eye irritation assessment
    Marisa Meloni
    VitroScreen, In Vitro Research Laboratories, Milano, Italy
    Toxicol In Vitro 24:276-85. 2010
    ....
  38. doi Ocular preservatives: associated risks and newer options
    Indu Pal Kaur
    University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
    Cutan Ocul Toxicol 28:93-103. 2009
    ..Reasons for discontinuing traditional preservatives and the need for less-toxic molecules are discussed at length, along with newer options coming up in this area...
  39. pmc A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients
    Antonio Martinez
    Glaucoma, Instituto Gallego de Oftalmologia, Santiago de Compostela, La Coruna, Spain
    J Ocul Pharmacol Ther 25:239-48. 2009
    ..To compare the effect on the retrobulbar hemodynamics and intraocular pressure (IOP) of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5% in patients with primary open-angle glaucoma (POAG)...
  40. ncbi Locally administered ocular corticosteroids: benefits and risks
    Charles N J McGhee
    Discipline of Ophthalmology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
    Drug Saf 25:33-55. 2002
    ..This extensive review assesses the therapeutic benefits of locally administered ocular corticosteroids in the context of the risks of adverse effects...
  41. ncbi Ocular symptoms and signs with preserved and preservative-free glaucoma medications
    N Jaenen
    UZ Sint Rafael, Leuven, Belgium
    Eur J Ophthalmol 17:341-9. 2007
    ..To compare the prevalence of side effects between eyedrops with or without preservatives, in terms of subjective symptoms and objective signs in patients with open-angle glaucoma...
  42. ncbi Are multidose over-the-counter artificial tears adequately preserved?
    Colin Charnock
    Department of Health Sciences, Oslo University College, Oslo, Norway
    Cornea 25:432-7. 2006
    ..Based on the challenge test outlined in the European Pharmacopoeia, products were tested in their original containers to see whether their component preservative had sufficient activity...
  43. doi An objective evaluation of eyedrop instillation in patients with glaucoma
    Jennifer L Stone
    Wilmer Eye Institute, The Johns Hopkins University, 6115 Falls Rd, Third Floor, Baltimore, MD 21209 2226, USA
    Arch Ophthalmol 127:732-6. 2009
    ..To evaluate the performance of patients with ocular hypertension and glaucoma who are experienced in the instillation of topical ocular hypotensive medications...
  44. pmc Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations
    Gary N Foulks
    Department of Ophthalmology and Vision Science, University of Louisville, 301 E Muhammad Ali Blvd, Louisville, KY 40202, USA
    Cornea 29:781-8. 2010
    ....
  45. ncbi Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen cha
    Mark B Abelson
    Ora, Inc, Andover, Massachusetts 01810, USA
    Clin Ther 31:1908-21. 2009
    ..Based on a history of clinical effectiveness and tolerability of oral bepotastine besilate in the treatment of allergic symptoms, bepotastine besilate is being tested as a potential ophthalmic medication for allergic conjunctivitis...
  46. ncbi Acute corneal epithelial change after instillation of benzalkonium chloride evaluated using a newly developed in vivo corneal transepithelial electric resistance measurement method
    Masafumi Uematsu
    Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
    Ophthalmic Res 39:308-14. 2007
    ..Acute corneal permeability change after instillation of benzalkonium chloride (BAC) was evaluated using a newly developed in vivo corneal transepithelial electric resistance (TER) measurement method...
  47. ncbi Dry eye in diabetic patients
    Igor Kaiserman
    Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel
    Am J Ophthalmol 139:498-503. 2005
    ..To compare the prevalence of keratoconjunctivitis sicca (KCS) in a prospective cohort of 22,382 diabetic patients with that in the general population...
  48. pmc Changes in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0. 12% unoprostone
    J Shimazaki
    Department of Ophthalmology, Tokyo Dental College, Chiba, Japan
    Br J Ophthalmol 84:1250-4. 2000
    ..A beta blocker (0.5% timolol) and a novel prostaglandin F(2alpha) metabolite related drug (0.12% unoprostone) were examined in a prospective, randomised fashion...
  49. doi Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production
    Stephen C Pflugfelder
    Ocular Surface Center, Baylor College of Medicine, Houston, TX, USA
    Cornea 27:64-9. 2008
    ..To evaluate the effects of sequential treatment with artificial tears and cyclosporine emulsion on conjunctival goblet cell density and production of transforming growth factor (TGF)-beta2 in patients with dry eye disease...
  50. ncbi The pathology of dry eye: the interaction between the ocular surface and lacrimal glands
    M E Stern
    Department of Biological Sciences, Allergan, Inc, Irvine, CA 92713 9534, USA
    Cornea 17:584-9. 1998
    ....
  51. ncbi Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies
    Gang Wei
    School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
    J Control Release 83:65-74. 2002
    ..However, no further improvement in the ocular retention was observed when adding HA-Na into the thermosetting gel due to the substantially decreased gel strength...
  52. ncbi Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects
    William C Stewart
    Pharmaceutical Research Network, Charleston, SC 29412 2464, USA
    J Glaucoma 12:475-9. 2003
    ..To evaluate short-term conjunctival and corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy individuals...
  53. ncbi Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension
    J Thygesen
    Department of Ophthalmology, Vejle Sygehus, Denmark
    Acta Ophthalmol Scand 78:37-44. 2000
    ..To investigate and compare the short term effects of topical latanoprost and timolol on the tear fluid and ocular surface condition in patients with bilateral primary open angle glaucoma or ocular hypertension...
  54. ncbi The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study
    Avni Murat Avunduk
    Louisiana State University, School of Medicine, LSU Eye Center, New Orleans, Louisiana, USA
    Am J Ophthalmol 136:593-602. 2003
    ....
  55. ncbi New vehicle based on a microemulsion for topical ocular administration of dexamethasone
    Silvia Ligorio Fialho
    Laboratory of Pharmaceutical Technology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
    Clin Experiment Ophthalmol 32:626-32. 2004
    ..The present study describes the development and characterization of an oil-in-water microemulsion containing dexamethasone and the evaluation of its pharmacokinetics in rabbits after topical ocular application...
  56. ncbi Comparative randomised active drug controlled clinical trial of a herbal eye drop in computer vision syndrome
    Pranab Kr Chatterjee
    Susrut Eye Foundation and Research Centre, Kolkata
    J Indian Med Assoc 103:397-8. 2005
    ..01) and almost identical results were observed with tears plus (difference was not statistically significant). Itone is considered to be a useful drug in computer vision syndrome...
  57. doi Evaluation of calcium dobesilate for its anti-cataract potential in experimental animal models
    T Velpandian
    Department of Ocular Pharmacology and Pharmacy, All India Institute of Medical Sciences, New Delhi, India
    Methods Find Exp Clin Pharmacol 32:171-9. 2010
    ..Anti-cataract activity may be due to its antioxidant as well as aldose reductase inhibitor properties. Further studies are in progress to evaluate its clinical efficacy in diabetic cataract...
  58. doi Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer
    Michael Ottiger
    ESBATech AG, Schlieren, Switzerland
    Invest Ophthalmol Vis Sci 50:779-86. 2009
    ..This study was designed to characterize ocular penetration pathways of ESBA105, a topically administered single-chain antibody (scFv) against tumor necrosis factor (TNF)-alpha, to the anterior and posterior segment of the eye...
  59. ncbi Effect of an oil-in-water emulsion on the tear physiology of patients with mild to moderate dry eye
    Santosh Khanal
    Department of Vision Sciences, Glasgow Caledonian University, Glasgow, United Kingdom
    Cornea 26:175-81. 2007
    ..To determine the effect of an oil-in-water emulsion eye drop compared with a conventional dry eye supplement (hypromellose) on tear physiology in dry eye...
  60. doi A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial
    Minjie Chen
    Department of Ophthalmology, Eye and ENT Hospital of Fudan University, Shanghai, China
    J Ocul Pharmacol Ther 26:361-6. 2010
    ..The goals of this study were to compare the efficacy and safety profile of topical cyclosporine 0.05% versus vehicle in Chinese patients with moderate to severe dry eye disease...
  61. doi Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits
    Amany Hassan Mohamed El-Shazly
    Ocular Pharmacology Department, Research Institute of Ophthalmology, Giza, Egypt
    Acta Pharm 58:163-73. 2008
    ..The use of selective COX-2 inhibitor, nimesulide, is preferred to avoid local and systemic side effects which may occur with the use of the nonselective COX inhibitor, ketorolac...
  62. doi Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty
    Edward J Holland
    Cincinnati Eye Institute, Edgewood, KY, USA
    Cornea 27:314-9. 2008
    To compare the corneal and aqueous penetration and pharmacokinetics of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions and their effect on corneal reepithelialization after penetrating keratoplasty.
  63. ncbi Effect of 5-S-GAD on UV-B-induced cataracts in rats
    Hiroyoshi Kawada
    Department of Ophthalmology, Kanazawa Medical University, Ishikawa, Japan
    Jpn J Ophthalmol 53:531-5. 2009
    ..This is a report of an investigation of the effect of 5-S-GAD (eyedrops) on UVB-induced cataracts in rats...
  64. ncbi Impact of deep freezing on the stability of 25 mg/ml vancomycin ophthalmic solutions
    V Sautou-Miranda
    Laboratoire de Pharmacie Clinique et Biotechnique, Faculte de Pharmacie, BP38, Place Henri Dunant, 63001, Clermont Ferrand Cedex, France
    Int J Pharm 234:205-12. 2002
    For the treatment of certain eye infections, ophthalmic solutions 'laced' with 25 mg/ml vancomycin are sometimes prepared...
  65. ncbi Topical cyclosporin A in the management of vernal keratoconjunctivitis
    V Gupta
    Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi
    Eye (Lond) 15:39-41. 2001
    ..To study the efficacy of topical cyclosporin A in children with vernal keratoconjunctivitis in a prospective randomised double-masked trial...
  66. ncbi The effects of beta-blockers on ocular blood flow in patients with primary open angle glaucoma: a color Doppler imaging study
    R Altan-Yaycioglu
    Department of Ophthalmology, Istanbul University, Istanbul Faculty of Medicine, Turkey
    Eur J Ophthalmol 11:37-46. 2001
    ..To evaluate the effects of four commonly used beta-blockers on ocular blood flow in patients with primary open angle glaucoma (POAG)...
  67. ncbi Effect of artificial tears on tear stress test
    Santosh Khanal
    Department of Vision Sciences, Glasgow Caledonian University, 70 Cowcaddens Road, Glasgow, United Kingdom
    Optom Vis Sci 85:732-9. 2008
    ..To determine the effect of two artificial tears of different viscosities in the relief of environmental dry eye induced with a novel tear stress test (TST)...
  68. pmc Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study
    P Prabhasawat
    Department of Ophthalmology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    Br J Ophthalmol 91:47-50. 2007
    ..To assess the short-term efficacy of hypotonic 0.18% sodium hyaluronate in patients with evaporative tear-sufficient dry eye due to lipid tear deficiency (LTD)...
  69. ncbi Preservative use in topical glaucoma medications
    Charles S Tressler
    Pfizer Inc, New York, New York 10017, USA
    Ocul Surf 9:140-58. 2011
    ..Individual clinical trials have shown that exposure to BAK concentrations contained in ophthalmic solutions does not produce adverse sequelae in the majority of glaucoma patients, but concerns continue with regard ..
  70. ncbi Suppression of experimental immune-mediated blepharoconjunctivitis in Brown Norway rats by topical application of FK506
    Koji Nishino
    Department of Ophthalmology, Kochi Medical School, Nankoku, Japan
    Graefes Arch Clin Exp Ophthalmol 240:137-43. 2002
    ..We investigated the possible inhibition of EC in BN rats by topical application of FK506, which is an immunosuppressive agent that mainly targets T cells...
  71. doi Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones
    Michelle C Callegan
    Molecular Pathogenesis of Eye Infections Research Center, Dean A McGee Eye Institute, Oklahoma City, Oklahoma, USA
    Adv Ther 26:447-54. 2009
    ..This study was designed to compare the kill rates of ophthalmic solutions of fourth-generation fluoroquinolones against isolates of common ocular bacterial pathogens.
  72. pmc Comparison between Ringer's lactate and balanced salt solution on postoperative outcomes after phacoemulsfication: a randomized clinical trial
    Viraj Vasavada
    IOL Research Centre, Raghudeep Eye Clinic, Memnagar, Ahmedabad, India
    Indian J Ophthalmol 57:191-5. 2009
    ..To compare the effects of balanced salt solution (BSS) and Ringer's lactate (RL) on corneal thickness, endothelial morphology, and postoperative anterior chamber inflammation in eyes undergoing phacoemulsification...
  73. ncbi The Effect of instilled fluorescein solution volume on the values and repeatability of TBUT measurements
    Michael E Johnson
    School of Optometry and Vision Sciences, Cardiff University, Cardiff, United Kingdom
    Cornea 24:811-7. 2005
    ....
  74. doi Chitosan based nanocarriers for indomethacin ocular delivery
    Alia A Badawi
    Department of Pharmaceutics and Industrial Pharmacy, Pharmacy College, Cairo University, Cairo, Egypt
    Arch Pharm Res 31:1040-9. 2008
    ..Therefore, CS nanocarriers developed in this study were able to contact intimately with the cornea providing slow gradual IM release with long-term drug level thereby increasing delivery to both external and internal ocular tissues...
  75. ncbi Allergy to ophthalmic preservatives
    Jison Hong
    UMDNJ New Jersey Medical School, Newark, USA
    Curr Opin Allergy Clin Immunol 9:447-53. 2009
    ..The purpose of the present review is to examine the hypersensitivity reactions to preservatives in topical ophthalmic therapies...
  76. ncbi A review of olopatadine for the treatment of ocular allergy
    Mark B Abelson
    Harvard Medical School and Schepens Eye Research Institute, Boston, Massachusetts, USA
    Expert Opin Pharmacother 5:1979-94. 2004
    ..In the future, a new formulation containing 0.2% olopatadine exhibits a duration of action up to 24 h, supporting once-daily dosing...
  77. pmc Bacterial contamination of ophthalmic solutions used in an extended care facility
    Danny H Kauffmann Jokl
    Department of Ophthalmology, Westchester Medical Center, New York Medical College, New York, USA
    Br J Ophthalmol 91:1308-10. 2007
    To assess the frequency of contamination of ophthalmic solutions in a long-term care facility and to describe the characteristics of contaminated solutions.
  78. ncbi Preserved and unpreserved 12 anti-allergic ophthalmic solutions and ocular surface toxicity: in vitro assessment in four cultured corneal and conjunctival epithelial cell lines
    Masahiko Ayaki
    Department of Ophthalmology, Saitama National Hospital
    Biocontrol Sci 15:143-8. 2010
    In the present study, we evaluated the cytotoxicity of anti-allergic ophthalmic solutions in cultured corneal and conjunctival cells, namely SIRC (rabbit corneal epithelium), BCE C/D-1b (bovine corneal epithelial cells), RC-1 (rabbit ..
  79. ncbi Effects of acetylcysteine and dexamethasone on experimental corneal wounds in rabbits
    A A Sarchahi
    Department of Clinical Studies, University of Shiraz, Shiraz, Iran
    Ophthalmic Res 40:41-8. 2008
    ..It is concluded that treatment of the eyes by a combination of 3% acetylcysteine and 0.1% dexamethasone (if used from the first day of ulceration) may retard the corneal wound healing in rabbits...
  80. pmc The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study
    Andrea P Martin
    Dpto Bioquímica Clínica, Facultad Ciencias Quimicas, Universidad Nacional de Cordoba, Argentina
    BMC Ophthalmol 3:2. 2003
    ..05% on biochemical markers of inflammation on conjunctival cells in patients with AC...
  81. ncbi Precorneal residence time of artificial tears measured in dry eye subjects
    Jerry R Paugh
    Southern California College of Optometry, 2575 Yorba Linda Boulevard, Fullerton, CA 92831, USA
    Optom Vis Sci 85:725-31. 2008
    ..The purpose of this investigation was to measure the precorneal residence time of saline and five marketed artificial tears in dry eye subjects using fluorometry...
  82. pmc Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis
    M Kidd
    Department of General Practice, The University of Sydney, Sydney, NSW, Australia
    Br J Ophthalmol 87:1206-11. 2003
    ..These multiple, pharmacological mechanisms provided the rationale for assessing the efficacy and safety of ketotifen 0.025% eye drops in subjects with seasonal allergic conjunctivitis (SAC) in an environmental setting...
  83. doi Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss
    Amy L Hennessy
    Glaucoma Specialists, Baltimore, Maryland, USA
    Ophthalmology 117:2345-52. 2010
    ..Objectively evaluate the ability of visually disabled glaucoma patients to successfully administer a single drop onto their eye...
  84. ncbi Rapid anti-inflammatory action of azelastine eyedrops for ongoing allergic reactions
    Giorgio Ciprandi
    Allergy and Immunology Clinic, Department of Internal Medicine, Genoa University, Genoa, Italy
    Ann Allergy Asthma Immunol 90:434-8. 2003
    ..Some second-generation antihistamines have anti-inflammatory activities, but the clinical relevance of this property is still unclear...
  85. doi Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial
    Mehmet Borazan
    Department of Ophthalmology, Baskent University School of Medicine, Ankara, Turkey
    Acta Ophthalmol 87:549-54. 2009
    ..the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC).
  86. ncbi A 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy
    Paul Palmberg
    University of Miami Miller School of Medicine, Bascom Palmer Eye Institute, Miami, Florida 33136, USA
    Eur J Ophthalmol 20:708-18. 2010
    ..To evaluate the efficacy and safety of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy...
  87. ncbi Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells
    Masahiko Ayaki
    Department of Ophthalmology, Fujigaoka Hospital, Showa University School of Medicine, Aobaku Yokohama, Kanagawa, Japan
    Clin Experiment Ophthalmol 36:553-9. 2008
    The cytotoxicity of a range of commercial ophthalmic solutions in the presence and absence of preservatives was assessed in human corneal endothelial cells (HCECs), corneal epithelia and conjunctival epithelia using in vitro techniques.
  88. pmc Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients
    D L Easty
    Department of Ophthalmology, Bristol Eye Hospital, UK
    Br J Ophthalmol 90:574-8. 2006
    ..This comparative, open design, phase III study was to assess the non-inferiority of the non-preserved T-Gel 0.1% single dose unit (SDU) versus its preserved multidose (MD) reference...
  89. doi Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis
    Thomas T Macejko
    Eye Care Associates of Greater Cincinnati, Inc, Fairfield, Ohio, USA
    Am J Ophthalmol 150:122-127.e5. 2010
    To evaluate the effectiveness of bepotastine besilate ophthalmic solutions 1.0% and 1...
  90. ncbi A pre-application drop containing carboxymethylcellulose can reduce multipurpose solution-induced corneal staining
    Jerry R Paugh
    Southern California College of Optometry, Fullerton, Fullerton, California 92831, USA
    Optom Vis Sci 84:65-71. 2007
    ..In vitro data suggest that carboxymethylcellulose (CMC) may neutralize polyhexanides. The purpose of this investigation was to determine whether a pre-application drop of CMC reduces polyhexanide staining in vivo...
  91. ncbi Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models
    T Sengoku
    Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co, Ltd, Kashima, Yodogawa ku, Osaka, Japan
    Clin Exp Allergy 33:1555-60. 2003
    ..It is well-known that FK506 strongly inhibits cytokine production by T cells in vitro. However, less evidence is available from in vivo studies of ocular allergy...
  92. ncbi The dilution of benzalkonium chloride (BAK) in the tear film
    Mitchell H Friedlaender
    Scripps Clinic, La Jolla, California, USA
    Adv Ther 23:835-41. 2006
    ....
  93. ncbi [Evaluation of effectiveness of Catalin eyedrops in patients with presenile and senile cataract]
    Jarosław Kociecki
    Kliniki Okulistycznej Akademii Medycznej w Poznaniu
    Klin Oczna 106:778-82. 2004
    ..Evaluation of effectiveness of Catalin eye drops in inhibition of cataract or eventual influence on regression of actually present opacities...
  94. ncbi Multilayered amniotic membrane transplantation for severe ulceration of the cornea and sclera
    K Hanada
    Department of Ophthalmology, Tokyo Dental College, Chiba, Japan
    Am J Ophthalmol 131:324-31. 2001
    ..To examine the efficacy of amniotic membrane transplantation in the treatment of deep corneal and scleral ulcers...
  95. ncbi Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen
    Rosario Pignatello
    Dipartimento di Scienze Farmaceutiche, Universita degli Studi di Catania, Citta Universitaria, Viale A Doria, 6 95125, Catania, Italy
    Eur J Pharm Sci 16:53-61. 2002
    ..Drug levels in the aqueous humour were also higher after application of the nanosuspensions; moreover, IBU-loaded nanosuspensions did not show toxicity on ocular tissues...
  96. ncbi Corneal and conjunctival changes caused by commonly used glaucoma medications
    Robert J Noecker
    Department of Ophthalmology, University of Arizona, Tucson, Arizona 85711, USA
    Cornea 23:490-6. 2004
    ..To evaluate the extent of epithelial corneal and conjunctival changes associated with prolonged use of topical glaucoma medications...
  97. ncbi Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca
    Bradley Strong
    Ocular Surface Center, Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas 77030, USA
    Cornea 24:80-5. 2005
    ..The purpose of this study is to determine if topical CsA treatment inhibits conjunctival epithelial apoptosis in a murine model of KCS...
  98. ncbi Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation
    Eric D Donnenfeld
    External Disease Cornea Department, Manhattan Eye, Ear and Throat Hospital, New York, New York, USA
    Ophthalmology 114:1653-62. 2007
    ..To evaluate the efficacy and ocular safety of bromfenac ophthalmic solution 0.09% (Xibrom) for the treatment of postoperative inflammation and reduction of ocular pain in subjects who have undergone cataract extraction (CE)...
  99. ncbi The effect of a topical antioxidant formulation including N-acetyl carnosine on canine cataract: a preliminary study
    David L Williams
    Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, CB3 OES, England, UK
    Vet Ophthalmol 9:311-6. 2006
    ..To determine the efficacy of a topical antioxidant formulation including N-acetyl carnosine in the treatment of canine cataract in a preliminary nonplacebo, controlled, unmasked study...
  100. ncbi Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease
    David R Hardten
    Minnesota Eye Consultants, Minneapolis, MN 55404, USA
    Curr Med Res Opin 23:2083-91. 2007
    ..Irvine, California) improves clinical outcomes when used adjunctively with topical cyclosporine 0.05% (Restasis, Allergan, Inc., Irvine, California) for the treatment of ocular surface disease...

Research Grants108 found, 100 shown here

  1. STATISITICAL DESIGN, MONITORING &COORD. OF VISION CLINICAL TRIALS &EPIDEMIOLOGY
    Keri Hammel; Fiscal Year: 2012
    ..Also, there will be a measurement of pressure in the eye and thickness of the cornea. To study patients'DNA, the researchers will obtain a bloo..
  2. Aspheric SDOCT Imaging System for Dry Eye and Cornea Diagnostics
    ERIC L BUCKLAND; Fiscal Year: 2012
    ....
  3. Topical Nanoparticles for CNV
    Uday B Kompella; Fiscal Year: 2010
    ..Such an approach avoids the pitfalls associated with invasive drug administrations. The proposed technologies are likely to benefit various drugs intended for treating diseases of the back of the eye. ..
  4. Ocular Drug Delivery Devices for Improved Postoperative Cataract Care
    Buddy D Ratner; Fiscal Year: 2010
    ....
  5. Lens crystallins: spatial location and properties in the ICR/f rat cataract model
    Stephen Barnes; Fiscal Year: 2010
    ..The ICR/f rat is a model to evaluate both new therapeutic interventions as well as risk factors in dietary supplements. ..
  6. Lens crystallins: spatial location and properties in the ICR/f rat cataract model
    Stephen Barnes; Fiscal Year: 2010
    ..The ICR/f rat is a model to evaluate both new therapeutic interventions as well as risk factors in dietary supplements. ..
  7. PROOF OF CONCEPT FOR ANTIMICROBIAL PROPERTIES OF LACRITIN IN VIVO
    John D Sheppard; Fiscal Year: 2010
    ....
  8. Transscleral Drug Delivery for Retinal Disorders
    Henry Edelhauser; Fiscal Year: 2009
    ..These delivery techniques should be safer and more effective than the state of the art. Ultimately, these results will guide us in enhancing drug treatments in ophthalmic practice. ..
  9. Transscleral Drug Delivery for Retinal Disorders
    Henry Edelhauser; Fiscal Year: 2006
    ..These delivery techniques should be safer and more effective than the state of the art. Ultimately, these results will guide us in enhancing drug treatments in ophthalmic practice. ..
  10. Transscleral Drug Delivery for Retinal Disorders
    HENRY FRANCIS EDELHAUSER; Fiscal Year: 2010
    ..These delivery techniques should be safer and more effective than the state of the art. Ultimately, these results will guide us in enhancing drug treatments in ophthalmic practice. ..
  11. Transscleral Drug Delivery for Retinal Disorders
    Henry Edelhauser; Fiscal Year: 2007
    ..These delivery techniques should be safer and more effective than the state of the art. Ultimately, these results will guide us in enhancing drug treatments in ophthalmic practice. ..
  12. Modifiable Risk Factors for CME in Retinitis Pigmentosa
    MICHAEL SANDBERG; Fiscal Year: 2009
    ....
  13. Modifiable Risk Factors for CME in Retinitis Pigmentosa
    Michael A Sandberg; Fiscal Year: 2010
    ....
  14. Drug Eluting Contact Lenses
    JOSEPH CIOLINO; Fiscal Year: 2009
    ..More importantly, they would offer the possibility of treating eye diseases with a host of medications that cannot currently be delivered in a drop form. ..
  15. Drug Eluting Contact Lenses
    Joseph B Ciolino; Fiscal Year: 2010
    ..More importantly, they would offer the possibility of treating eye diseases with a host of medications that cannot currently be delivered in a drop form. ..
  16. Molecular and Clinical Pharmacology of Retinopathy of Prematurity
    Jacob V Aranda; Fiscal Year: 2011
    ..ROP is the most common cause of blindness in children. Understanding the molecular events leading to ROP and providing novel, effective and safe drug interventions will avert a lifetime of blindness, disability and darkness. ..
  17. Subconjunctival Sirolimus in the Treatment of AMD Bilateral Geographic Atrophy
    Darby Thompson; Fiscal Year: 2009
    ..Blood tests. Blood is drawn at the first visit and at up to seven study visits to check blood chemistries, such as liver and kidney function. - Urine pregnancy test for women who are able to become pregnant. ..
  18. A Novel Treatment for Keratoconus and Keratectasias using Nitro Technology
    David C Paik; Fiscal Year: 2010
    ..The latter conditions are devastating, long-term (5-10 years) complications following LASIK procedures. They were previously unpredicted and are currently of unknown epidemiologic proportion. ..
  19. A Novel Treatment for Keratoconus and Keratectasias using Nitro Technology
    David Paik; Fiscal Year: 2009
    ..The latter conditions are devastating, long-term (5-10 years) complications following LASIK procedures. They were previously unpredicted and are currently of unknown epidemiologic proportion. ..
  20. Ocular Insert for Non-Invasive Sustained Drug Delivery for the Treatment of Glauc
    CHARLES LEAHY; Fiscal Year: 2009
    ..It will also reduce the current 24-59% level of non-compliance by remaining in the eye between physician visits (1). ..
  21. Ocular Insert for Non-Invasive Sustained Drug Delivery for the Treatment of Glauc
    CHARLES DANIEL contact LEAHY; Fiscal Year: 2010
    ..It will also reduce the current 24-59% level of non-compliance by remaining in the eye between physician visits (1). ..
  22. OCULAR INSERT FOR THE TREATMENT OF GLAUCOMA
    CHARLES LEAHY; Fiscal Year: 2001
    ..Define a prototype design for a polymeric insert of the human inferior conjunctival sac. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE ..
  23. Advanced Imaging for Glaucoma
    David Huang; Fiscal Year: 2009
    ..Accurate monitoring of glaucoma with OCT will improve treatment decisions regarding surgery or eye drops, both of which are effective but also carry significant side effects and risks. ..
  24. Advanced Imaging for Glaucoma
    David Huang; Fiscal Year: 2010
    ..Accurate monitoring of glaucoma with OCT will improve treatment decisions regarding surgery or eye drops, both of which are effective but also carry significant side effects and risks. ..
  25. Advanced Imaging for Glaucoma
    David Huang; Fiscal Year: 2010
    ..Accurate monitoring of glaucoma with OCT will improve treatment decisions regarding surgery or eye drops, both of which are effective but also carry significant side effects and risks. ..
  26. Low-Cost Device for Digital Retinal Imaging
    ANN ELSNER; Fiscal Year: 2003
    ..Finally, we will examine the image quality of this low cost LSDC for functions such as angiography. ..
  27. Low-Cost Device for Digital Retinal Imaging
    ANN ELSNER; Fiscal Year: 2004
    ..Finally, we will examine the image quality of this low cost LSDC for functions such as angiography. ..
  28. Low-Cost Device for Digital Retinal Imaging
    ANN ELSNER; Fiscal Year: 2004
    ..Finally, we will examine the image quality of this low cost LSDC for functions such as angiography. ..
  29. Low-Cost Device for Digital Retinal Imaging
    ANN ELSNER; Fiscal Year: 2005
    ..Finally, we will examine the image quality of this low cost LSDC for functions such as angiography. ..
  30. Age-Related Eye Disease Study (AREDS) Follow-Up
    Darby Thompson; Fiscal Year: 2010
    ..NOTE: AREDS is funded through a variety of mechanisms. This support contract is involved in administrative management of the project. ..
  31. Drug Discovery for Diabetic Retinopathy
    ZOYA DEMIDENKO; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  32. Ultra-Sonic Non-Contact Tonometer in Glaucoma-IOP Checks
    Peter Gross; Fiscal Year: 2005
    ..Phase I of the project will end with a working model of the USNCT that demonstrates the feasibility of the method in a model eye with IOP controlled by intracameral manometry. ..
  33. Bioartificial Lacrimal Gland
    Samuel Yiu; Fiscal Year: 2004
    ....
  34. Bioartificial Lacrimal Gland
    Samuel Yiu; Fiscal Year: 2005
    ....
  35. A Real Time Monitoring System to Measure IOP in Glaucoma
    DOUG JACKSON; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  36. A Real Time Monitoring System to Measure IOP in Glaucoma
    DOUG JACKSON; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  37. TIME RELEASE OPHTHALMIC DRUG DELIVERY INSERT
    BRUCE COHAN; Fiscal Year: 2000
    ..In The United States alone glaucoma affects at least 3 million people and involves a pharmaceutical market of $785 million. ..
  38. DEVICE TO AID SELF ADMINISTRATION OF EYEDROPS
    GEORGE FRIED; Fiscal Year: 2000
    ..It will be a simple, low cost device with large health and cost benefits to the public. ..
  39. DEVICE TO AID SELF ADMINISTRATION OF EYEDROPS
    GEORGE FRIED; Fiscal Year: 2001
    ..It will be a simple, low cost device with large health and cost benefits to the public. ..
  40. ANTIMICROBIAL PEPTIDES TO TREAT BACTERIAL KERATITIS
    KATHRYN CRAWFORD; Fiscal Year: 2004
    ..determine the chemical and toxicological suitability of these molecules for use as potential antimicrobial ophthalmic solutions. The Specific Aims of Phase I are to 1): Conduct pre-formulation studies designed to develop suitable ..
  41. TIME RELEASE OPHTHALMIC DRUG DELIVERY INSERT
    BRUCE COHAN; Fiscal Year: 2002
    ..proposed commercial application: not available ..
  42. TIME RELEASE OPHTHALMIC DRUG DELIVERY INSERT
    BRUCE COHAN; Fiscal Year: 2001
    ..proposed commercial application: not available ..
  43. A Phase II Study of OT-551 Antioxidant Eye Drop
    Darby Thompson; Fiscal Year: 2009
    ..Participants will have one eye randomized to receive the eye drop and the fellow eye will be observed only. ..
  44. Age-Related Eye Disease Study (AREDS) Follow-Up
    Darby Thompson; Fiscal Year: 2009
    ..Photographs of the inside of the eye may be taken using a special camera that flashes a bright light in the eye. A blood sample may be obtained to test for cholesterol level and genes related to inflammation. ..
  45. Naltrexone as a Novel Treatment for Diabetic Keratopathy
    IAN ZAGON; Fiscal Year: 2007
    ..The proposed use of biotherapy with NTX is an innovative approach whereby the patient's own growth regulatory mechanisms are manipulated to correct complications from diabetes. ..
  46. Gene Gun Technology, Opioids, and Corneal Diseases
    IAN ZAGON; Fiscal Year: 2003
    ..Ultimately, such data can be employed to design molecular strategies to remedy visual dysfunction. ..
  47. COLLABORATIVE INITIAL GLAUCOMA TREATMENT STUDY
    Henry Jampel; Fiscal Year: 2002
    ....
  48. EARLY DETECTION OF GLAUCOMA DAMAGE
    Susan Vitale; Fiscal Year: 2001
    ..This assessment of the RTA and NFA will help to establish their utility as outcome measures for clinical management of glaucoma, epidemiological research, and clinical trials. ..
  49. EARLY DETECTION OF GLAUCOMA DAMAGE
    Susan Vitale; Fiscal Year: 2002
    ..This assessment of the RTA and NFA will help to establish their utility as outcome measures for clinical management of glaucoma, epidemiological research, and clinical trials. ..
  50. EARLY DETECTION OF GLAUCOMA DAMAGE
    Henry Jampel; Fiscal Year: 2004
    ..This assessment of the RTA and NFA will help to establish their utility as outcome measures for clinical management of glaucoma, epidemiological research, and clinical trials. ..
  51. EARLY DETECTION OF GLAUCOMA DAMAGE
    Susan Vitale; Fiscal Year: 2000
    ..This assessment of the RTA and NFA will help to establish their utility as outcome measures for clinical management of glaucoma, epidemiological research, and clinical trials. ..
  52. EARLY DETECTION OF GLAUCOMA DAMAGE
    Henry Jampel; Fiscal Year: 2003
    ..This assessment of the RTA and NFA will help to establish their utility as outcome measures for clinical management of glaucoma, epidemiological research, and clinical trials. ..
  53. GLAUCOMA SURGICAL OUTCOMES STUDY
    Henry Jampel; Fiscal Year: 2000
    ..The results of the study may allow physicians to reduce the morbidity of glaucoma surgery by altering their indications for surgery, surgical technique, and postoperative follow-up. ..
  54. GLAUCOMA SURGICAL OUTCOMES STUDY
    Henry Jampel; Fiscal Year: 2001
    ..The results of the study may allow physicians to reduce the morbidity of glaucoma surgery by altering their indications for surgery, surgical technique, and postoperative follow-up. ..
  55. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2001
    ..Finally, the interactions between comorbidities (including cognitive deficits) and visual field loss will be explored. ..
  56. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2003
    ..Finally, the interactions between comorbidities (including cognitive deficits) and visual field loss will be explored. ..
  57. PREVALENCE AND IMPACT OF GLAUCOMA AMONG THE VERY ELDERLY
    David Friedman; Fiscal Year: 2002
    ..Finally, the interactions between comorbidities (including cognitive deficits) and visual field loss will be explored. ..
  58. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    HARRY ALAN QUIGLEY; Fiscal Year: 2010
    ..To complete the project in 2 years, we eliminated from the 5 year proposal Hypotheses 7, 8, 9, and 11. ..
  59. Localized modulation of RPE P-gp/MRP activity for back-of-the-eye drug delivery
    Soumyajit Majumdar; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  60. Multiethnic Pediatric Eye Disease Study (MEPEDS)
    Rohit Varma; Fiscal Year: 2007
    ..MEPEDS will also be studying selected demographic, biological and behavioral risk factors associated with these diseases and the consequences of these diseases from a health related quality of life perspective. ..
  61. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 1999
    ..In these rats, induced neuronal expression will be studied in a chronic glaucoma model to assess beneficial effects. ..
  62. MOLECULAR STUDIES OF THE THIEL-BEHNKE CORNEAL DYSTROPHY
    Richard Yee; Fiscal Year: 2005
    ....
  63. Localized modulation of RPE P-gp/MRP activity for back-of-the-eye drug delivery
    Soumyajit Majumdar; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  64. Mechanisms of Inflammation and Vision Loss in Endophthalmitis
    Michelle Callegan; Fiscal Year: 2009
    ..By identifying the bacterial and host factors important in disease, we can exploit these targets for the development of new treatment strategies that will increase the likelihood of preventing blindness following endophthalmitis. ..
  65. OCULAR HYPERTENSION TREATMENT STUDY (OHTS)
    Donald Budenz; Fiscal Year: 2008
    ....
  66. Dry Eye in Postmenopause
    Kelly K Nichols; Fiscal Year: 2010
    ..This project is a unique blend of interdisciplinary clinical and basic research, which may lead to the translation of findings to clinical care in dry eye disease. ..
  67. Mechanisms of Inflammation and Vision Loss in Endophthalmitis
    Michelle C Callegan; Fiscal Year: 2010
    ..By identifying the bacterial and host factors important in disease, we can exploit these targets for the development of new treatment strategies that will increase the likelihood of preventing blindness following endophthalmitis. ..
  68. Dry Eye in Postmenopause
    Kelly Nichols; Fiscal Year: 2008
    ..This project is a unique blend of interdisciplinary clinical and basic research, which may lead to the translation of findings to clinical care in dry eye disease. ..
  69. PATHOGENIC MECHANISMS OF BACILLUS CEREUS ENDOPHTHALMITIS
    Michelle Callegan; Fiscal Year: 2001
    ..Identification and characterization of important virulence factors will provide the basis on which information-based therapeutic agents are developed in order to prevent vision loss during B. cereus endophthalmitis. ..
  70. Pathogenesis & Chemotherapy of Bacillus Endophthalmitis
    Michelle Callegan; Fiscal Year: 2005
    ....
  71. PATHOGENIC MECHANISMS OF BACILLUS CEREUS ENDOPHTHALMITIS
    Michelle Callegan; Fiscal Year: 2003
    ..Identification and characterization of important virulence factors will provide the basis on which information-based therapeutic agents are developed in order to prevent vision loss during B. cereus endophthalmitis. ..
  72. PATHOGENIC MECHANISMS OF BACILLUS CEREUS ENDOPHTHALMITIS
    Michelle Callegan; Fiscal Year: 2002
    ..Identification and characterization of important virulence factors will provide the basis on which information-based therapeutic agents are developed in order to prevent vision loss during B. cereus endophthalmitis. ..
  73. PATHOGENIC MECHANISMS OF BACILLUS CEREUS ENDOPHTHALMITIS
    Michelle Callegan; Fiscal Year: 2002
    ..Identification and characterization of important virulence factors will provide the basis on which information-based therapeutic agents are developed in order to prevent vision loss during B. cereus endophthalmitis. ..
  74. OCULAR HYPERTENSION TREATMENT STUDY (OHTS)
    Donald Budenz; Fiscal Year: 2007
    ....
  75. Pathogenesis & Chemotherapy of Bacillus Endophthalmitis
    Michelle Callegan; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  76. OCULAR HYPERTENSION TREATMENT STUDY (OHTS)
    Donald Budenz; Fiscal Year: 2004
    ....
  77. PATHOGENESIS OF CORNEAL EDEMA AFTER INTRAOCULAR SURGERY
    Henry Edelhauser; Fiscal Year: 2000
    ....
  78. THE PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 1980
  79. PATHOGENESIS OF CORNEAL EDEMA AFTER INTRAOCULAR SURGERY
    Henry Edelhauser; Fiscal Year: 1992
    ....
  80. PATHOGENESIS OF CORNEAL EDEMA AFTER INTRAOCULAR SURGERY
    Henry Edelhauser; Fiscal Year: 1999
    ....
  81. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 1991
    ....
  82. PATHOGENESIS OF CORNEAL EDEMA AFTER INTRAOCULAR SURGERY
    Henry Edelhauser; Fiscal Year: 2001
    ....
  83. P30- Core Grant for Vision Research
    Henry Edelhauser; Fiscal Year: 2008
    ..The Core facilities also serve a role in the research projects of our pre- and postdoctoral fellows supported by our departmental NEI Training Grant (T32 EY007092-19), recently renewed for the next five years (2004-2009). ..
  84. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2006
    ..The studies proposed here have already suggested several new avenues of non-intraocular pressure lowering therapy for glaucoma. ..
  85. Wilmer Inst. Mentored Clinical Research Scholar Program
    Harry Quigley; Fiscal Year: 2008
    ..The Wilmer CRS will administer didactic courses and personal mentored instruction in a wide variety of research areas to 2 candidates per year. ..
  86. PATHOGENESIS OF GLAUCOMATOUS OPTIC NERVE DAMAGE
    Harry Quigley; Fiscal Year: 2008
    ..Candidate molecules for genetic susceptibility to glaucoma are likely to be identified. ..
  87. PATHOGENESIS OF CORNEAL EDEMA AFTER INTRAOCULAR SURGERY
    Henry Edelhauser; Fiscal Year: 2006
    ....
  88. PATHOGENESIS OF CORNEAL EDEMA AFTER INTRAOCULAR SURGERY
    Henry Edelhauser; Fiscal Year: 2005
    ....